Premium
Bronchogenic carcinoma in young patients
Author(s) -
Whooley Brian P.,
Urschel John D.,
Antkowiak Joseph G.,
Takita Hiroshi
Publication year - 1999
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199905)71:1<29::aid-jso6>3.0.co;2-v
Subject(s) - medicine , pneumonectomy , lung cancer , surgery , adenocarcinoma , univariate analysis , carcinoma , radiation therapy , stage (stratigraphy) , wedge resection , cancer , retrospective cohort study , multivariate analysis , resection , paleontology , biology
Background and Objectives Some investigators have suggested that lung cancer in young patients has a more aggressive course and poorer prognosis than lung cancer in older patients. Methods A retrospective review is presented of patients less than 40 years of age with bronchogenic carcinoma treated at Roswell Park Cancer Institute between 1984 and 1994, with comparison to a cohort of patients treated in the previous decade. Results There were 76 patients (41 male and 35 female). Mean age was 35 years (range, 26–39). Adenocarcinoma in 33 patients (43%) and undifferentiated large‐cell carcinoma in 22 patients (29%) were the predominant histologic types. Stage IIIa or greater disease was present in 63 (83%) patients. Treatment consisted of chemotherapy (55 patients), radiation therapy (54 patients), and surgery (33 patients). Surgical procedures included pneumonectomy (14 patients), lobectomy (11 patients), wedge resection (1 patient), and thoracotomy only for unresectable disease (7 patients). Operative mortality was 6% (two patients who had radical pneumonectomy for T4 cancer). Median survival for the entire group of patients was 10.4 months, and 5‐year survival was 8%. Univariate analysis identified acute presentation ( P = 0.02), no resection ( P = 0.0001), and higher stage ( P = 0.0001) as negative prognostic factors. On multivariate analysis, stage of disease was the only independent predictor of survival ( P = 0.005). Resectability was slightly higher (34%, 26/76, vs. 21%, 19/89; P = 0.06) and survival was marginally better (median 10.4 vs. 7.5 months; P = 0.05) than that seen at our institution in the previous decade. Conclusions Young patients with lung cancer often have advanced disease at the time of presentation. Nevertheless, they should be treated in accordance with standard stage‐specific treatment guidelines. J. Surg. Oncol. 1999:71:29–31. © 1999 Wiley‐Liss, Inc.